Superficial fungal infections: An update on pityriasis versicolor, seborrheic dermatitis, tinea capitis, and onychomycosis

Clinics in Dermatology

Volumn 21, Issue 5, 2003, Pages 417-425

  Gupta, Aditya K ^a   Ryder, Jennifer E ^a   Nicol, Karyn ^a   Cooper, Elizabeth A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLYLAMINE DERIVATIVE; AMOROLFINE; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROX; CORTICOSTEROID; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; METRONIDAZOLE; MICONAZOLE; PROPYLENE GLYCOL; PYRIDONE DERIVATIVE; PYRITHIONE ZINC; PYRROLE DERIVATIVE; SELENIUM SULFIDE; TACROLIMUS; TERBINAFINE;

ATOPIC DERMATITIS; ATROPHY; CANDIDA PARAPSILOSIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALASSEZIA; MALASSEZIA FURFUR; MALASSEZIA PACHYDERMATIS; MYCOSIS; NONHUMAN; ONYCHOMYCOSIS; PARASITE TRANSMISSION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SEBORRHEIC DERMATITIS; SIDE EFFECT; TINEA CAPITIS; TINEA VERSICOLOR; TREATMENT OUTCOME;

EID: 0346996355     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2003.08.003     Document Type: Article

References (103)

1. Sugita T., Takashima M., Shinoda T., et al. New yeast species, Malassezia dermatis, isolated from patients with atopic dermatitis. J Clin Microbiol. 40:2002;1363-1367.
2. Hafez M., El-Shamy S. Genetic susceptibility in pityriasis versicolor. Dermatologica. 171:1985;86-88.
3. Scheynius A., Faergemann J., Forsum U., et al. Phenotypic characterization in situ of inflammatory cells in pityriasis (tinea) versicolor. Acta Derm Venereol (Stockh). 64:1984;473-479.
4. Parry M.E., Sharpe G.R. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 139:1998;254-263.
5. Faergemann J., Bergbrant I.-M., Dohsé M., et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis characterization of inflammatory cells and mediators in the skin by immunohistochemistry . Br J Dermatol. 144:2001;549-556.
6. Crespo Erchiga V., Delgado Florencio V. Malassezia species in skin diseases. Curr Opin Infect Dis. 15:2002;133-142.
7. ® dermgel . Dermatology. 197:1997;19-21.
8. Aspiroz C., Ara M., Varea M., et al. Isolation of Malassezia globosa and M. sympodialis from patients with pityriasis versicolor in Spain. Mycopathologia. 154:2002;111-117.
9. Crespo Erchiga V., Ojeda Martos A., Vera Casano A., et al. Mycology of pityriasis versicolor. J Mycol Med. 9:1999;143-148.
10. Gupta A.K., Kohli Y., Faergemann J., et al. Epidemiology of Malassezia yeasts associated with pityriasis versicolor in Ontario, Canada. Med Mycol. 39:2001;199-206.
11. Gupta AK, Batra R, Bluhm R, et al Pityriasis versicolor. Dermatol Clin 2003;21:413-14.
12. Gupta A.K., Del Rosso J.Q. An evaluation of intermittent therapies used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol. 39:2000;401-411.
13. Jones H.E. Pityriasis versicolor with ketoconazole (reply to letter). J Am Acad Dermatol. 20:1989;704-705.
14. Shemer A., Nathansohn N., Kaplan B., et al. Itraconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatol Treatment. 10:1999;19-23.
15. Farshcian M., Yaghoobi R., Samadi K. Fluconazole versus ketoconazole in the treatment of tinea versicolor. J Dermatol Treatment. 13:2002;73-76.
16. Köse O., Bülent Tastan H., Riza Gür A., et al. Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. J Dermatol Treatment. 13:2002;77-79.
17. Montero-Gei F., Robles M.E., Suchil P. Fluconazole vs. itraconazole in the treatment of tinea versicolor. Int J Dermatol. 38:1999;601-603.
18. Hickman J.G. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol. 34:1996;785-787.
19. Cuce L.C., Belda W., Ribeiro E.B.O. Itraconazole in the treatment of pityriasis versicolor comparison between 5 and 7 days of treatment . Rev Inst Med Trop Sao Paulo. 32:1990;181-184.
20. Galimberti R.L., Villalba I., Galarza S., et al. Itraconazole in pityriasis versicolor ultrastructural changes in Malassezia furfur produced during treatment . Rev Infect Dis. 9:1987;S134-138.
21. Massone L., Pestarino A., Borghi S., et al. Oral itraconazole in the treatment of pityriasis versicolor a comparison of two different dosage regimens . Micologia Dermatologica. 5:1991;90-92.
22. Del Palacio-Hernanz A., Vicente S.D., Ramos F.M., et al. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis. 9:1987;S121-127.
23. Estrada R.A. Itraconazole in pityriasis versicolor. Rev Infect Dis. 9:1987;S128-130.
24. Morales-Doria M. Pityriasis versicolor efficacy of two five-day regimens of itraconazole . Rev Infect Dis. 9:1987;S131-133.
25. Del Palacio Hernanz A., Frias Iniesta J., Gonzalez Valle O., et al. Itraconazole therapy in pityriasis versicolor. Br J Dermatol. 115:1986;217-225.
26. Simoni S., Cilli P. Itraconazole in the treatment of pityriasis versicolor results obtained in 30 patients . G Ital Dermatol Venereol. 126:1991;41-43.
27. Panconesi E., Difonzo E. Treatment of dermatophytoses and pityriasis versicolor with itraconazole. Rev Infect Dis. 9:1987;S109-113.
28. Shahid J., Ihsan Z., Khan S. Oral fluconazole in the treatment of pityriasis versicolor. J Dermatol Treatment. 11:2000;101-103.
29. Am M.A., Abdallah M.A., Abdel-Aal M.A., et al. Fluconazole in the treatment of tinea versicolor. Int J Dermatol. 36:1997;938-946.
30. Faergemann J., Gupta A.K., Al Mofadi A., et al. Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. Arch Dermatol. 138:2002;69-73.
31. Ashbee H.R., Evans E.G. Immunology of diseases associated with Malassezia species. Clin Microbiol Rev. 15:2002;21-57.
32. Ford G.P., Farr P.M., Ive F.A., et al. The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol. 111:1984;603-607.
33. Gupta A.K., Yokou M., Arika T., et al. Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against Malassezia furfur species and seborrheic dermatitis. J Dermatol Treatment. 11:2000;79-83.
34. Gupta AK, Bluhm R, Cooper EA, et al. Seborrheic dermatitis. Dermatol Clin 2003;21:401-12.
35. Caputo R., Barbareschi M. Itraconazole new horizons . G Ital Dermatol Venereol. 137:2002;1-7.
36. ®) in patients with seborrhoeic dermatitis. A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 144:2001;854-857.
37. Ling M.R. Topical tacrolimus and pimecrolimus future directions . Semin Cutan Med Surg. 20:2001;268-274.
38. Rausch L.J., Jacobs P.H. Tinea versicolor treatment and prophylaxis with monthly administration of ketoconazole . Cutis. 34:1984;470-471.
39. Peter R.U., Richarz-Barthauer U. Successful treatment and prophylaxis of scalp seborrhoeic dermatitis and dandruff with 2% ketoconazole shampoo results of a multicentre, double-blind, placebo-controlled trial . Br J Dermatol. 132:1995;441-445.
40. Lipozencic J., Skerlev M., Orofino R., et al. A randomized, double-blind, parallel-group duration finding study of oral terbinafine in children with tinea capitis due to Microsporum species. Br J Dermatol. 146:(5):2002;816-823.
41. Friedlander S.F., Aly R., Krafchik B., et al. Terbinafine in the treatment of Trichophyton tinea capitis a randomized, double-blind, parallel group duration-finding study . Pediatr. 109:(4):2002;602-607.
42. Romero, G, Garrido, JA, Cortina, P, et al Efficacy of oral terbinafine in children with tinea capitis caused by Microsporum canis. J Eur Acad Dermatol Venereol 1998;11(Suppl 2):S236.
43. Suarez S., Fallon Friedlander S. Antifungal therapy in children an update . Pediatr Ann. 27:1998;177-184.
44. Williams J., Honig P., McGinley K., et al. Semiquantitative study of tinea capitis and the asymptomatic carrier state in inner-city school children. Pediatr. 96:1995;265-267.
45. Wilmington M., Aly R., Frieden I.J. Trichophyton tonsurans tinea capitis in the San Francisco Bay area increased infection demonstrated in a 20-year survey of fungal infections from 1974-1994 . J Med Vet Mycol. 34:1996;285-287.
46. Gupta A.K., Summerbell R.C. Increased incidence of Trichophyton tonsurans tinea capitis in Ontario, Canada between 1985 and 1996. Med Mycol. 36:1998;55-60.
47. Gupta A.K., Summerbell R.C. Tinea capitis. Med Mycol. 38:2000;255-287.
48. Friedlander S.F. The evolving role of itraconazole, fluconazole, and terbinafine in the treatment of tinea capitis. Pediatr Infect Dis J. 18:1999;205-210.
49. Gupta A.K., Adam P., Dlova N., et al. Therapeutic options for the treatment of tinea capitis caused by Trichophyton species griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole . Pediatr Dermatol. 18:(5):2001;433-438.
50. Clayton Y.M. In vitro activity of terbinafine. Clin Exp Dermatol. 14:1989;101-103.
51. Gupta AK, Cooper EA, Lynde CW. The efficacy and safety of terbinafine in children. Dermatol Clin (Submitted 2003).
52. Burkhart C.G. Coffee grinders assist pediatric dosing. Cutis. 65:(5):2000;276.
53. Koumantaki E., Kakourou T., Rallis E., et al. Doubled dose of oral terbinafine is required for Microsporum canis tinea capitis. Pediatr Dermatol. 18:(4):2001;339-342.
54. Pierini, AM, Soliani, A, Hernandez, M, et al Treatment of tinea capitis due to Microsporum canis with oral terbinafine: 40 cases. Ann Dermatol Venereol 1998;125(Suppl 1):1S133.
55. Friedlander, SF, Skerlev, M, Lipozencic, J, et al Relationship between terbinafine dose and complete cure rate in tinea capitis: analysis of phase II randomized trials. J Eur Acad Dermatol Venereol 2001;15(Suppl 2):221.
56. Gupta AK, Cooper EA, Ginter G. Efficacy and safety of itraconazole in children. Dermatol Clin (Submitted 2003).
57. Gupta A.K., Hofstader S.L.R., Summerbell R.C., et al. Treatment of tinea capitis with itraconazole capsule pulse therapy. J Am Acad Dermatol. 39:1998;216-219.
58. Gupta A.K., Adam P., De Doncker P. Itraconazole pulse therapy for tinea capitis a novel treatment schedule . Pediatr Dermatol. 15:1998;225-228.
59. Gupta A.K., Alexis M.E., Raboobee N., et al. Itraconazole pulse therapy is effective in the treatment of tinea capitis in children an open multicenter study . Br J Dermatol. 137:1997;251-254.
60. Gupta A.K., Solomon R., Adam P. Itraconazole oral solution for the treatment of tinea capitis. Br J Dermatol. 139:1998;104-106.
61. Gupta A.K., Adam P., Solomon R., et al. Itraconazole oral solution for the treatment of tinea capitis using the pulse regimen. Cutis. 64:1999;192-194.
62. Goa K.L., Barradell L.B. Fluconazole-An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs. 50:1995;658-690.
63. Canadian Pharmacists Association. Diflucan™-Pfizer-Fluconazole- Antifungal Agent. In Compendium of Pharmaceuticals and Specialties (CPS) 2002, Edition 37. Toronto: Webcom Limited. 2002:502-5.
64. Gupta AK, Cooper EA, Montero-Gei F. The use of fluconazole to treat superficial fungal infections in children. Dermatol Clin 2003;21:537-42.
65. Pomeranz A.J., Sabnis S.S., McGrath G.J., et al. Asymptomatic dermatophyte carriers in the households of children with tinea capitis. Arch Pediatr Adolesc Med. 153:1999;483-486.
66. Frieden I.J. Tinea capitis asymptomatic carriage of infection . Pediatr Infect Dis J. 18:(2):1999;186-190.
67. Neil G., Hanslo D., Buccimazza S., et al. Control of the carrier state of scalp dermatophytes. Pediatr Infect Dis J. 9:(1):1990;57-58.
68. Greer D.L. Treatment of symptom-free carriers in management of tinea capitis. Lancet. 348:(9024):1996;350-351.
69. Hebert A.A. Tinea capitis. Curr Concepts Arch Dermatol. 124:1988;1554-1557.
70. Higgins E.M., Fuller L.C., Smith C.H. Guidelines for the management of tinea capitis. Br J Dermatol. 143:2000;53-58.
71. Drake L.A., Dinehart S.M., Farmer E.R., et al. Guidelines of care for superficial mycotic infections of the skin tinea capitis and tinea barbae . J Am Acad Dermatol. 34:1996;290-294.
72. Honig P.J. Tinea capitis recommendations for school attendance . Pediatr Infect Dis J. 18:1999;211-214.
73. Gupta A.K. Onychomycosis in the elderly. Drugs Aging. 16:(6):2000;397-407.
74. Gupta A.K., Lynde C.W., Jain H.C., et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics a multicenter study . Br J Dermatol. 136:1997;786-789.
75. Gupta A.K., Taborda P., Taborda V., et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 39:(10):2000;746-753.
76. Gupta A.K., Gupta M.A., Summerbell R.C., et al. The epidemiology of onychomycosis possible role of smoking and peripheral arterial disease . J Eur Acad Dermatol Venereol. 14:(6):2000;466-469.
77. Gupta A.K., Jain H.C., Lynde C.W., et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians' offices a multicenter Canadian survey of 15, 000 patients . J Am Acad Dermatol. 43:2000;244-248.
78. Gupta, AK, Ryder, J. How to improve cure rates for the management of onychomycosis. Dermatol Clin 2003;21:499-505.
79. Gupta, AK, Ryder, J, Baran, R. The use of topical therapies to treat onychomycosis. Dermatol Clin 2003;21:481-89.
80. Gupta, AK, Ryder, J. The use of oral antifungal agents to treat onychomycosis. Dermatol Clin 2003;21:469-79.
81. Ginter G., Rieger E., Heigl K., et al. Increasing frequency of onychomycosis - is there a change in the spectrum of infectious agents? Mycoses. 39:(Suppl. 1):1996;118-122.
82. Gupta A.K., Sauder D.N., Shear N.H. Antifungal agents an overview Part I . J Am Acad Dermatol. 30:1994;677-698.
83. Gupta A.K., Sauder D.N., Shear N.H. Antifungal agents an overview Part II . J Am Acad Dermatol. 30:1994;911-933.
84. Segal R., Kritzman A., Cividalli L., et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol. 35:1996;958-961.
85. Nolting S., Brautigam M., Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophytic fungi. Br J Dermatol. 130:(Suppl 43):1994;16-21.
86. Gupta A.K., Shear N.H. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis. Drug Safety. 22:(1):2000;33-52.
87. Gupta A.K., Horgan-Bell C.B., Summerbell R.C. Onychomycosis associated with Onychocola canadensis ten case reports and a review of the literature . J Am Acad Dermatol. 39:1998;410-417.
88. Gupta A.K., Elewski B.E. Nondermatophyte causes of onychomycosis and superficial mycoses. Curr Top Med Mycol. 7:(1):1996;87-97.
89. Gupta A.K., De Doncker P., Scher R.K., et al. Itraconazole for the treatment of onychomycosis. Int J Dermatol. 37:1998;303-308.
90. Gupta A.K., Gregurek-Novak T., Konnikov N., et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg. 5:(3):2001;206-210.
91. Evans E.G.V., Sigurgeirsson B. Double blind, randomized study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ. 318:1999;1031-1035.
92. Heikkilä H., Stubb S. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. Br J Dermatol. 146:2002;250-253.
93. Sigurgeirsson B., Olafsson J.H., Steinsson J.B., et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis a 5-year blinded prospective follow-up study . Arch Dermatol. 138:(3):2002;353- 357.
94. Crawford F., Young P., Godfrey C., et al. Oral treatments for toenail onychomycosis a systematic review . Arch Dermatol. 138:2002;811-816.
95. Cribier B.J., Paul C. Long-term efficacy of antifungals in toenail onychomycosis a critical review . Br J Dermatol. 145:2001;446-452.
96. De Cuyper C., Hindryckx P.H.F.B. Long-term outcomes in the treatment of toenail onychomycosis. Br J Dermatol. 141:(Suppl 56):1999;15-20.
97. Haugh M., Helou S., Boissel J.P., et al. Terbinafine in fungal infections of the nails a meta-analysis of randomized clinical trials . Br J Dermatol. 147:(1):2002;118-121.
98. Farkas B., Paul C., Dobozy A., et al. Terbinafine (Lamisil®) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus a multicenter trial . Br J Dermatol. 146:2002;254-260.
99. Hay R.J. The future of onychomycosis therapy may involve a combination of approaches. Br J Dermatol. 145:(Suppl 60):2001;3-8.
100. Gupta A. Exploring regimens to improve efficacy in the treatment of onychomycosis. [Abstract] Ann Dermatol Venereol. 129:2002;1S664.
101. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol. 145:(Suppl 60):2001;15-19.
102. Baran R., Feuilhade M., Datry A., et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the matrix region. Br J Dermatol. 142:2000;1177-1183.
103. Lecha M. Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. Br J Dermatol. 145:(Suppl 60):2001;21-26.